Dissemination of prostate adenocarcinoma to the skull base mimicking giant trigeminal schwannoma: anatomic relevance of the extradural neural axis component

Clinical Anatomy of the Extradural Neural Axis Compartment: A Literature Review

OBJECTIVE

The extradural neural axis compartment (EDNAC) is an adipovenous zone located between the meningeal and endosteal layers of the dura and has been minimally investigated. It runs along the neuraxis from the orbits down to the coccyx and contains fat, valveless veins, arteries, and nerves. In the present review, we have outlined the current knowledge regarding the structural and functional significance of the EDNAC.

METHODS

We performed a narrative review of the reported EDNAC data.

RESULTS

The EDNAC can be organized into 4 regional enlargements along its length: the orbital, lateral sellar, clival, and spinal segments, with a lateral sellar orbital junction linking the orbital and lateral sellar segments. The orbital EDNAC facilitates the movement of the eyeball and elsewhere allows limited motility for the meningeal dura. The major nerves and vessels are cushioned and supported by the EDNAC. Increased intra-abdominal pressure will also be conveyed along the spinal EDNAC, causing increased venous pressure in the spine and cranium. From a pathological perspective, the EDNAC functions as a low-resistance, extradural passageway that might facilitate tumor encroachment and expansion.

CONCLUSIONS

Clinicians should be aware of the extent and significance of the EDNAC, which could affect skull base and spine surgery, and have an understanding of the tumor spread pathways and growth patterns. Comparatively little research has focused on the EDNAC since its initial description. Therefore, future investigations are required to provide more information on this underappreciated component of neuraxial anatomy.

Symptomatic Meckel's Cave Metastasis from Castration-resistant Prostate Cancer Treated with Gamma Knife Radiosurgery

Prostate cancer commonly spreads to the axial and appendicular skeleton, but metastases to the brain parenchyma or skull base are uncommon. In the cases that this happens, the symptoms are usually associated with disease involving the orbit. Metastasis to the Meckel’s cave causing trigeminal nerve palsy is an exceedingly rare entity. We are presenting a case of this in a man with metastatic castration-resistant prostate cancer. Metastatic prostate cancer to the Meckel's cave is extremely uncommon, and there is no standard of care. Radiation therapy, especially radiosurgery, is increasingly recognized as an excellent alternative to surgery for lesions in the Meckel’s cave and intracranial/skull base prostate cancer metastases. Gamma Knife radiosurgery (Elekta, Stockholm, Sweden), in particular, has been reported to achieve local control close to 90% for calvarial and skull base metastases with few side effects and requires only one treatment. Our patient’s 1.4 x 1.0 x 1.3 cm metastatic prostate cancer lesion in the Meckel's cave was treated with Gamma Knife to 22 Gy with good treatment response including rapid improvement in his symptoms and no side effects. We review the scarce literature documenting cases of prostate cancer metastatic to the brain or skull base and the only two other documented cases of prostate cancer metastasis the Meckel’s cave neither of which was treated with radiotherapy.

Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence

There is increasing recognition of the involvement of the immune signaling molecule, tumor necrosis factor (TNF), in the pathophysiology of stroke and chronic brain dysfunction. TNF plays an important role both in modulating synaptic function and in the pathogenesis of neuropathic pain. Etanercept is a recombinant therapeutic that neutralizes pathologic levels of TNF. Brain imaging has demonstrated chronic intracerebral microglial activation and neuroinflammation following stroke and other forms of acute brain injury. Activated microglia release TNF, which mediates neurotoxicity in the stroke penumbra. Recent observational studies have reported rapid and sustained improvement in chronic post-stroke neurological and cognitive dysfunction following perispinal administration of etanercept. The biological plausibility of these results is supported by independent evidence demonstrating reduction in cognitive dysfunction, neuropathic pain, and microglial activation following the use of etanercept, as well as multiple studies reporting improvement in stroke outcome and cognitive impairment following therapeutic strategies designed to inhibit TNF. The causal association between etanercept treatment and reduction in post-stroke disability satisfy all of the Bradford Hill Criteria: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy. Recognition that chronic microglial activation and pathologic TNF concentration are targets that may be therapeutically addressed for years following stroke and other forms of acute brain injury provides an exciting new direction for research and treatment.